April 19, 2019
Authored and Edited by Scott A. Allen; M. Andrew Holtman, Ph.D.
In January 2019, in conjunction with Version 1.0 of its Working Model for the Software Precertification Program, FDA issued a 2019 Test Plan for testing the software precertification model before employing it as a full-scale alternative premarket pathway for software as a medical device (“SaMD”) products. The primary purpose of the Test Plan is to assess whether the Excellence Appraisal process and Streamlined Review components of the precertification program, as described in the Working Model, together produce an equivalent basis for determining reasonable assurance of safety and effectiveness for SaMD products.
The Test Plan will consist of retrospective and prospective testing on a series of test cases. For retrospective testing, FDA will extract elements that are proposed to be included in a Streamlined Review from a previously-reviewed, complete submission package for a SaMD product. FDA will review this set of product-specific data then determine what additional information not supplied by the Streamlined Review package would be needed to determine an assurance of safety and effectiveness. FDA will then review the proposed Excellence Appraisal elements to confirm that, if an Excellence Appraisal had been conducted, the questions remaining for the review of the product would be answered during an Excellence Appraisal.
For prospective testing, FDA intends to use a mock Streamlined Review package for a group of selected premarket submissions. Specifically, FDA will conduct an Excellence Appraisal with the sponsor, but require the sponsor to also submit traditional marketing submissions. FDA staff would assemble a mock Streamlined Review package and an independent review team would then evaluate whether it can determine sufficient information from the Excellence Appraisal elements to provide an assurance of safety and effectiveness. If the review team finds gaps in evidence in the mock Streamlined Review package, the team would request unmasking of specific elements from the full submission. FDA envisions the prospective testing to be an iterative process.
At the conclusion of the 2019 Test Plan, FDA intends to have demonstrated that the totality of evidence collected through the Excellence Appraisal and Streamlined Review processes align to and satisfy the regulatory requirements for making a determination of reasonable assurance of safety and effectiveness.
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.